Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer-Reference-Cited by-同舟云学术

Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer

Published:2017-03-04 Issue:25 Volume:8 Page:41631-41640
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Hong Xiangchan¹,Chen Qi²,Ding Lingyu³,Liang Ying¹,Zhou Ningning¹,Fang Wenfeng¹,Chen Xinru¹,Wu Haiying¹

Affiliation:

1. Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China

2. Department of Oncology, The First Affiliated Hospital of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, China

3. Department of Medical Oncology, Hangzhou Cancer Hospital, Hangzhou, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alectinib continuation beyond progression in ALK-positive non-small cell lung cancer with alectinib-refractory;Translational Lung Cancer Research;2024-01

2. The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies;Journal of Thoracic Disease;2022-06

3. Long-Term Survival After Salvage Thoracic Surgery on a Patient with ALK-Rearranged Metastatic Lung Adenocarcinoma After Progression on Targeted Therapy;OncoTargets and Therapy;2021-11

4. The impact of baseline brain metastases on clinical benefits and progression patterns after first-line crizotinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer;Medicine;2021-02-26

5. Crizotinib versus chemotherapy: a real-world cost–effectiveness study in China;Journal of Comparative Effectiveness Research;2020-02